Table 5.
Association of TIER1 hotspot mutations with precancers and cancers by HPV type/groups among samples collected within 2 years of outcome ascertainment
| HPV type/group | Status | Total | No HS mutation | HS mutations | P | OR | 95%CI | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N, ≥ 1 HS | % | |||||||
| HPV16 | Control | 665 | 645 | 97.0% | 20 | 3.0% | ref | |||
| CIN2 | 244 | 238 | 97.5% | 6 | 2.5% | 0.66 | 0.81 | 0.32 | 2.05 | |
| CIN3/AIS | 844 | 798 | 94.5% | 46 | 5.5% | 0.02 | 1.86 | 1.09 | 3.17 | |
| CIN3 | 750 | 714 | 95.2% | 36 | 4.8% | 0.09 | 1.63 | 0.93 | 2.84 | |
| AIS | 94 | 84 | 89.4% | 10 | 10.6% | 8.8 × 10−4 | 3.84 | 1.74 | 8.48 | |
| Cancer | 103 | 75 | 72.8% | 28 | 27.2% | 4.2 × 10−15 | 12.04 | 6.47 | 22.42 | |
| SCC | 50 | 31 | 62.0% | 19 | 38.0% | 6.7 × 10−16 | 19.77 | 9.58 | 40.77 | |
| ADC | 43 | 35 | 81.4% | 8 | 18.6% | 1.0 × 10−5 | 7.37 | 3.03 | 17.91 | |
| N | % | N,PIK3CA | % | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 648 | 645 | 99.5% | 3 | 0.5% | ref | ||||
| Cancer | 93 | 75 | 80.6% | 18 | 19.4% | 5.4 × 10−10 | 51.60 | 14.85 | 179.28 | |
| SCC | 42 | 31 | 73.8% | 11 | 26.2% | 1.5 × 10−10 | 76.36 | 20.25 | 287.85 | |
| ADC | 41 | 35 | 85.4% | 6 | 14.6% | 7.3 × 10−7 | 36.90 | 8.85 | 153.81 |
| N | % | N, non-PIK3CA | % | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 659 | 645 | 97.9% | 14 | 2.1% | ref | ||||
| Cancer | 83 | 75 | 90.4% | 8 | 9.6% | 5.3 × 10−4 | 4.91 | 2.00 | 12.10 | |
| SCC | 37 | 31 | 83.8% | 6 | 16.2% | 2.7 × 10−5 | 8.92 | 3.21 | 24.78 | |
| ADC | 37 | 35 | 94.6% | 2 | 5.4% | 0.21 | 2.63 | 0.58 | 12.04 |
| HPV18/45 | N | % | N, ≥ 1 HS | % | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 557 | 543 | 97.5% | 14 | 2.5% | Ref | ||||
| CIN2 | 210 | 204 | 97.1% | 6 | 2.9% | 0.79 | 1.14 | 0.43 | 3.01 | |
| CIN3/AIS | 159 | 154 | 96.9% | 5 | 3.1% | 0.66 | 1.26 | 0.45 | 3.55 | |
| CIN3 | 108 | 107 | 99.1% | 1 | 0.9% | 0.33 | 0.36 | 0.05 | 2.79 | |
| AIS | 50 | 46 | 92.0% | 4 | 8.0% | 0.04 | 3.37 | 1.07 | 10.67 | |
| Cancer | 38 | 30 | 78.9% | 8 | 21.1% | 1.2 × 10−6 | 10.34 | 4.03 | 26.56 | |
| SCC | 10 | 9 | 90.0% | 1 | 10.0% | 0.18 | 4.31 | 0.51 | 36.37 | |
| ADC | 27 | 20 | 74.1% | 7 | 25.9% | 4.3 × 10−7 | 13.57 | 4.94 | 37.31 |
| N | % | N,PIK3CA | % | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 547 | 543 | 99.3% | 4 | 0.7% | ref | ||||
| Cancer | 34 | 30 | 88.2% | 4 | 11.8% | 7.4 × 10−5 | 18.14 | 4.32 | 76.07 | |
| SCC | 10 | 9 | 90.0% | 1 | 10.0% | 0.02 | 15.12 | 1.54 | 148.95 | |
| ADC | 23 | 20 | 87.0% | 3 | 13.0% | 1.5 × 10−4 | 20.39 | 4.28 | 97.24 |
| N | % | N, non-PIK3CA | % | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 553 | 543 | 98.2% | 10 | 1.8% | ref | ||||
| Cancer | 34 | 30 | 88.2% | 4 | 11.8% | 1.4 × 10−3 | 7.24 | 2.15 | 24.44 | |
| SCC | 9 | 9 | 100.0% | 0 | 0.0% | 0.93 | - | - | - | |
| ADC | 24 | 20 | 83.3% | 4 | 16.7% | 1.7 × 10−4 | 10.87 | 3.14 | 37.66 |
CIN2 cervical intraepithelial neoplasia grade 2, CIN3 CIN grade 3, AIS adenocarcinoma in situ, SCC squamous cell carcinoma, ADC adenocarcinoma. Samples with co-occurrence of both PIK3CA and non-PIK3CA mutations were excluded from the analyses. HS hotspot; P = multinomial logistic regression, OR odds ratio, Cl confidence interval. Significant P-values are bolded. OR, 95%CI, and P-values were estimated using multinomial logistic regression; tests were two-sided.